News >

Tocilizumab Resolves CRS in Pediatric B-ALL Without Reducing Tisagenlecleucel Efficacy

Jason Harris
Published: Monday, May 21, 2018

blood cells Tocilizumab (Actemra) resolved cytokine release syndrome (CRS) in patients with relapsed/refractory pediatric B-cell acute lymphoblastic leukemia (B-ALL) without reducing the efficacy of tisagenlecleucel (Kymriah), according to results presented in a poster at the 2018 American Society of Pediatric Hematology/Oncology Conference.1


  1. Awasthi R, Lee C, Bittencourt H, et al. Pharmacokinetics and pharmacodynamics of tocilizumab for the management of cytokine release syndrome (CRS) in pediatric and young-adult patients with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL) treated with chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel (CTL019). Presented at: the 2018 ASPHO Conference; May 2-5, 2018; Pittsburgh, PA. Poster 709.
  2. FDA approves Genentech’s Actemra (tocilizumab) for the treatment of CAR T cell-induced cytokine release syndrome [news release]; 2018. Accessed May 11, 2018.
  3. Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018; 378:439-448.
  4. Schuster SJ, Bishop MR, Tam CS, et al. Primary analysis of Juliet: A global, pivotal, phase 2 trial of CTL019 in adult patients with relapsed or refractory diffuse large B-cell lymphoma. Presented at: ASH Annual Meeting and Exposition; Dec. 9-12, 2017; Atlanta. Abstract 577.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Individualizing Treatment After Second-Line Therapy for Patients With mCRCAug 29, 20191.0
Community Practice Connections™: Immunotherapeutic Strategies with the Potential to Transform Treatment for Genitourinary CancersAug 29, 20191.0
Publication Bottom Border
Border Publication